Weekly Case Studies

Home » News & Resources » Weekly Case Studies

Avoidance of Inappropriate De-escalation with T2Candida

Faster Time to Targeted Therapy with T2Bacteria

In both of these clinical case studies, T2Bacteria identified the causative pathogen days sooner than blood culture and allowed for the earlier initiation of targeted therapy.

Targeted Antibiotic Therapy in Endocarditis Case with T2Bacteria

A T2Bacteria result facilitated the diagnosis of infective endocarditis that led to the rapid initiation of targeted antibiotic therapy in a critically ill patient with prosthetic valve endocarditis. Fast species ID enabled targeted treatment 8 days before blood culture results were available.

Detection of Polymicrobial Infection in Critically Ill COVID-19 Patient

T2Bacteria enabled the detection of polymicrobial infection and the detection of a subsequent Enterococcus faecium infection in a patient where cultures remained negative. Rapid species identification led to targeted therapy and eventual discharge.

Secondary Candidemia in Critically Ill COVID-19 Patient

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.

T2Bacteria Identifies Causative Pathogen in a Critically Ill Patient with a Respiratory Infection

A 20-year-old patient with a history of lupus presented to the emergency department with shortness of breath.

Discussion

This case highlights the benefit of T2Bacteria’s rapid bacterial species identification, which enabled early identification of the causative pathogen in a critically ill, immunocompromised patient. Bacterial infections commonly occur following the successful treatment of viral infections. These infections are often missed due to prior antimicrobial use, especially in at-risk patient populations, leading to treatment delays and negative clinical outcomes.

Utilizing T2Candida Result to Impact Appropriate Therapy

A 67-year-old patient had experienced infections, including multi-drug resistant pneumonia, sepsis, and C. difficile colitis during admission.

Discussion

This case highlights the benefit of T2Candida’s rapid fungal species identification, which allowed for the continuation of appropriate antifungal therapy as well as the discontinuation of unnecessary broad-spectrum antibiotics, resulting in clinical improvement.

T2Bacteria Result Used to Alter Therapy

An elderly patient presented to the ED with a day-long history of fever, shaking, suprapubic pain, vomiting, and diarrhea

Discussion

This case highlights not only T2Bacteria’s ability of rapid identification but also the capability to detect the causative organism and use the result to de-escalate therapy.

T2Bacteria Positive while Cultures Remained Negative

An elderly patient presented to the ED with nausea, myalgia, and insomnia.

Discussion

This case highlights the benefit of the T2Bacteria Panel’s ability to provide species identification in the presence of antimicrobial therapy rapidly. Using T2Bacteria enabled the identification of E.coli in a patient on inadequate therapy for a urinary tract infection (UTI).

Rapid T2Bacteria Result Helps Prevent Potential Complications due to Premature Discharge

A patient was admitted with a two-day history of right lower quadrant pain, fever, and vomiting

Discussion

This case highlights the benefit of rapid species identification with the T2Bacteria Panel and the potential prevention of additional sequelae with a premature discharge from the ED.

According to the CDC, of the 154 million prescriptions for antibiotics written in doctors’ offices and emergency departments each year, 30% are unnecessary.¹²

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

JOIN IN ON TWITTER

T2 Biosystems

@T2Bio

Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.

March 31, 2023

T2 Biosystems

@T2Bio

Given the high attributable mortality and challenges with conventional diagnostic methods, the need for improved #rapiddiagnostics for #Candida species is evident. #whitepaper #diagnostics #fungi #fungalinfection #sepsis

March 30, 2023

SITEMAP

FOLLOW US ON SOCIAL

Please tell us where you are visiting from: United States | Outside the United States